Kazia Therapeutics announces presentation of EVT801

Kazia Therapeutics announces the presentation of data highlighting promising clinical activity of EVT801 in high grade serous, HGS, Ovarian Cancer at the 15th Biennial Ovarian Cancer Research Symposium, co-presented by American Association of Cancer Research, AACR, and the Rivkin Center for Ovarian Cancer Research on Saturday, September 21, 2024 in Seattle Washington. Key points of the presentation included: A total of 26 patients were treated across 6 dosing cohorts ranging from 50mg once daily (QD) to 500mg twice daily; Patients with eleven different cancer types were enrolled in the study, with heavily pretreated advanced ovarian cancer being the most prevalent indication; Biomarkers have shown strong VEGFR3 expression in multiple indications, including ovarian cancer; Encouraging clinical activity in High Grade Serous ovarian cancer patients with forty-six percent having stable disease or for at least three cycles, including two patients who received 9 cycles; One patient had a partial response after 2 cycles of EVT801 therapy